TATA HEALTH(01255): Zhang Mingqi has been transferred from a non-executive director to an executive director.

17:19 21/10/2025

TATA Health (01255) announced that Mr. Zhang Mingqi has been transferred from a non-executive director to an executive director, and has been appointed as...

TATA HEALTH (01255) announces that Mr. Zhang Mingqi, previously a non-executive director, has been appointed as an executive director and CEO of the company, effective from October 21, 2025. Mr. Xu Jianda will be appointed as the Chief Financial Officer of the company, effective from October 21, 2025.

Huadong Medicine (000963.SZ): The clinical trial application for DR10624 injection medication has been approved by the US FDA.

Shanghai Tongji Science & Technology Industrial (600846.SH) plans to reduce its holdings by up to 4.41552 million shares through share repurchases.

LAI FUNG HOLD (01125) announced its annual performance. The company's owners are expected to incur a loss of approximately HK$419 million, representing a 56.7% increase year-on-year.

Huadong Medicine (000963.SZ): The clinical trial application for DR10624 injection medication has been approved by the US FDA.

Shanghai Tongji Science & Technology Industrial (600846.SH) plans to reduce its holdings by up to 4.41552 million shares through share repurchases.

LAI FUNG HOLD (01125) announced its annual performance. The company's owners are expected to incur a loss of approximately HK$419 million, representing a 56.7% increase year-on-year.